Skip to main content
. 2018 Oct 8;32(4):doy093. doi: 10.1093/dote/doy093

Table 1.

Patient demographics all incident FIs

1976–1982 1983–1988 1989–1994 1995–2000 2001–2006 2007–2012 Total
(N = 31) N = 41) (N = 90) (N = 124) (N = 117) (N = 94) (N = 497) P value
Total impactions 31 41 90 124 117 94 497
Age at
incident FI
0.867*
 Median 61.3 57.8 57.2 53.9 50.6 54.6 54.5
 Q1, Q3 19.1, 74.9 34.8, 64.8 35.8, 71.4 32.4, 70.7 39.1, 76.1 34.2, 69.5 35.8, 71.9
 Range (0.0-84.1) (9.9-78.3) (1.0-95.3) (1.3-94.5) (10.8-99.1) (1.5-97.9) (0.0-99.1)
Female 13 (41.9%) 13 (31.7%) 35 (38.9%) 45 (36.3%) 52 (44.4%) 35 (37.2%) 193 (38.8%) 0.701**
Any allergic diathesis 20 (64.5%) 23 (56.1%) 51 (56.7%) 78 (62.9%) 69 (59.0%) 59 (62.8%) 300 (60.4%) 0.889**
 Asthma 6 (19.4%) 8 (19.5%) 18 (20.0%) 26 (21.0%) 16 (13.7%) 20 (21.3%) 94 (18.9%) 0.722**
 Allergic rhinitis 8 (25.8%) 7 (17.1%) 20 (22.2%) 23 (18.5%) 22 (18.8%) 26 (27.7%) 106 (21.3%) 0.533**
 Drug allergy 2 (6.5%) 7 (17.1%) 17 (18.9%) 37 (29.8%) 30 (25.6%) 20 (21.3%) 113 (22.7%) 0.064**
 Food allergy 3 (9.7%) 1 (2.4%) 4 (4.4%) 4 (3.2%) 8 (6.8%) 8 (8.5%) 28 (5.6%) 0.402**
 Eosinophilia 11 (35.5%) 7 (17.1%) 12 (13.3%) 30 (24.2%) 16 (13.7%) 17 (18.1%) 93 (18.7%) 0.036**
 Other 7 (22.6%) 5 (12.2%) 17 (18.9%) 20 (16.1%) 24 (20.5%) 19 (20.2%) 92 (18.5%) 0.793**
Medications
 H2 Blocker 0 (0.0%) 0 (0.0%) 6 (6.7%) 7 (5.6%) 6 (5.1%) 4 (4.3%) 23 (4.6%) 0.524***
 PPI 0 (0.0%) 0 (0.0%) 2 (2.2%) 3 (2.4%) 14 (12.0%) 19 (20.2%) 38 (7.6%) <0.001***
GERD 3 (9.7%) 2 (4.9%) 22 (24.4%) 25 (20.2%) 32 (27.4%) 44 (46.8%) 128 (25.8%) <0.001**
Dysphagia 14 (45.2%) 16 (39.0%) 42 (46.7%) 56 (45.2%) 74 (63.2%) 63 (67.0%) 265 (53.3%) <0.001**
Esophageal biopsy 3 (9.7%) 10 (24.4%) 16 (17.8%) 19 (15.3%) 49 (41.9%) 42 (44.7%) 139 (28%) <0.001**

*Kruskal Wallis; **Chi-Square; ***Fisher Exact.